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The complete hospital and community records of 77 women were randomly selected from 232 women who had relapsed breast
cancer between 2000 and 2005. Scrutiny of all management activities revealed a total cost of d1939329 (mean per patient of
d25186, 95% CI d13705–d33821). The median survival from time of relapse was 40.07 months and the median total cost per
patient was d31402.62. Including the community cost of a relapse provides a more realistic figure for future cost-effectiveness analysis
of adjuvant breast cancer therapies.
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Developments in adjuvant drugs such as herceptin, aromatase
inhibitors and taxanes, although initially expensive, reduce the risk
of relapse and hence have long-term financial benefits (Thomas
et al, 2006). To decide whether the benefits are cost-effective,
budget holders require an accurate knowledge of how much it
costs to treat patients with relapse. Most earlier estimates have
used predictive modelling or interviews with clinicians (Mansel
et al, 2007). A UK trial, now 6 years old, estimated hospital costs of
relapsed breast cancer by sending questionnaires to UK oncolo-
gists and produced a figure of d12500 per patient (Remak and
Brazil, 2004). A study from Edinburgh, collecting hospital data
from node-positive women, gave a figure of d13533 for loco-
regional relapse and d13193 for distant relapse (Karnon et al,
2007). We report the first analysis of the total hospital and
community cost of managing patients with relapsed breast cancer
from a typical UK breast cancer practice.
METHODS
The Bedford Breast Cancer database identified 232 women who
had relapsed between March 2000 and March 2005 with loco-
regional or distant disease. The identification codes were placed in
separate sealed envelopes and one-third (77) randomly selected for
data collection until their death or the predetermined end of the
study in January 2007. The average age of the cohort was 62.3 years
(33–95) and 44% were originally node positive; 67% post-
menopausal, 48% stage 1 (T1), 33% T2, 16% T3–4; 55% oestrogen
receptor (ER)
þve, 25% ER
 ve (25% unknown) and 21% over-
expressed human epithelial growth factor receptor (HER)2 (17%
unknown). The demographics of the entire group and selected
cohort were similar, indicating that the randomisation process was
balanced. The specific cancer-related activities were derived from
written and electronic hospital records (Table 1). For each patient,
a member of the research team visited all GP practices, hospices
and community offices to collect all the relapse-related manage-
ment and drug activities, which ensured there was no missing data.
Once complete, the data set was locked and analysed in liaison
with the Health Economics Department of Cranfield University.
The predetermined subgroups chosen were menopausal status, ER
status and HER2 expression, as these influence drug strategies on
relapse. Whether patients suffered local or distant relapse was not
included, as an earlier analysis did not demonstrate a cost
difference (Karnon et al, 2007).
The NHS tariffs for outpatient visits, procedures, nights in
hospital and investigations were derived from the existing NHS
Trust Reference Cost Index 2004 (DoH, 2004). Radiotherapy was
costed per fraction taken from the Reference Costs’ National
Average Unit Cost. General practitioner and district nurse visit
from the PCT Reference Cost Index (DoH, 2004). Hospital drug
costs included VAT and were the actual amount charged for each.
Community drugs (excluding VAT) and hospice (including VAT)
drug tariffs were taken from the British National formulary (BNF,
2005).
RESULTS
Of the 77 patients analysed in this study, 52 (67.5%) had died of
metastatic breast cancer by the end of the data-collection point,
January 2007, with a median survival of 40.1 months (Figure 1).
The first site of relapse was distant in 51 patients (66%) and loco-
regional in 26 (34%). The average time from initial diagnosis to
relapse was 71.2 months (range 4–173 months).
The total hospital and community cost of managing the 77
patients from relapse until death, or to the end of the evaluation
period, was d1939329 (mean d25186, 95% CI d13705–d33821).
Dividing the total cost by the total number of patient months
within the assessment period (2474.6) gave an average monthly Received 2 July 2008; revised 7 January 2009; accepted 11 January 2009
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scost of d783.7 per month. The median cost per patient derived
from the basic data was d19886.6. The median cost per patient
taking into account that not all patients died during the evaluation
period was also estimated by multiplying the monthly average by
the median survival (40.07), which gave a figure of d31402.62.
Nearly a third (30.3%) of the cost of a relapse lay in the
community and 69.7% in the hospital setting. The total drug cost
was 39% of the total. There was a non-statistically significant trend
for patients who were pre-menopausal (32), being subsequently
more expensive to manage on relapse than post-menopausal (45)
(ratio of mean cost per patient 1.44:1). Likewise, ER
 ve women
were more expensive to treat on relapse than ER
þve (61) (ratio
1.34:1). Women with tumours overexpressing HER2 were more
expensive to treat than HER2 normal (48) or those not tested (13)
(ratio 1.25:1). In this study cohort, only 7 of the 16 received
herceptin on relapse. There was no trend between those axillary
nodes positive (35) compared with those negative (21) or unknown
(21) (ratio 1.04:1).
DISCUSSION
The strength of this study lies in the comprehensiveness of the data
extracted from a typical breast cancer population treated within a
standard UK management framework. Collecting the data from
both hospital and community sources required substantial
co-operation from a wide range of professional groups, and a
Table 1 Categories of costs following relapse (77 patients)
Source 95% Confidence interval Mean Total
Community costs (d)
GP home visit GPDB 301 657 480 36950
GP appointments GPDB 772 1469 1121 86337
GP telephone calls GPDB 57 109 84 6432
Hospice nights GPBD 495 1796 1146 88241
Hospice visits HDB 25 118 72 5554
Palliative community telephone HBD 39 86 63 4824
Palliative community visits HDB 272 811 542 41743
Community district nurse INR 98 762 430 33124
GP-prescribed drugs GPDB 2350 4481 2916 263036
Hospice drugs HN 70 614 272 20954
Sub-total community costs 4479 10903 7126 d587195
Percentage total cost (d1939329) 30.3%
Hospital drugs
Outpatients’ hospital pharmacy PDB 3839 7940 5890 453495
Ward stores PDB 47 367 207 15963
Hospital bed costs
In-patients PIMS 2166 3802 2984 229789
Surgical interventions PIMS 733 1489 1112 85603
Blood transfusion HN 372 1044 708 54534
Outpatients’ visits
Outpatient consultation PIMS 2471 3602 3037 233849
Day/half-day case PIMS 1040 1981 1511 116352
ECG DR HN 41 83 63 4842
Radiotherapy RTDB 408 764 587 45166
Support services DR HN 48 106 78 5981
A and E admissions PIMS 129 213 171 13208
Hospital services
Radiology DDB 554 856 705 54322
Pathology DDB 292 459 376 28967
Transport DR 44 216 131 10062
Sub-total of hospital costs 9226 22918 17560 d1352134
Percentage of total costs (d1939329) 69.7%
Grand total d13705 d33821 d25186 d1939329
DDB¼departmental database; DR¼departmental written records; GPDB¼general practice database; HN¼hospital notes; INR¼individual nursing records; PDB¼pharmacy
database; PIMS¼Patient Information Management System; RTBD¼Addenbrooke’s oncology electronic database.
Kaplan–Meier survival curve
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Figure 1 Kaplan–Meier life table and survival curve for 77 patients from
date of relapse. Median survival 40.07 months (25 were alive at the time of
analysis).
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ssingle institution ameliorated the absence of missing data. This
advantage, however, is also the basis of a potential criticism if this
data were to be extrapolated nationally, as a single-institution
study may have been subject to skews in local demographics or
medical practice.
The demographics of the North Bedfordshire population,
obtained from 2003 government figures, however, appeared fairly
typical for the United Kingdom (Census, 2001). The average age
was in line with the national average as was the single, separated
and widowed population. The percentages of people with British
citizenship (91.4 vs 87.5%) and those born in the United Kingdom
(93.0 vs 91.1%) were similar. There was a slightly higher
percentage of the population working (42.6 vs 40.1%), and fewer
unemployed (2.6 vs 3.4%), but a similar percentage who achieved
higher educational qualifications (18.9 vs 19.8%). Breast cancer
management adhered to West Anglia Cancer Network guidance,
which had been developed from national advisory documents. Any
deviation from the guidance required formal documentation
through a concession form system.
The median overall survival for the patients relapsing at
our institution (40.7 months) was higher than the 10–20 months
reported in first-line metastatic studies in the United Kingdom
and Europe evaluating metastatic chemotherapy regimens
(Bontenbal et al, 2005), probably explained by our group
including 30% with loco-regional relapse only. Overall survival
was, however, comparable with the 20–30 months reported within
first-line metastatic aromatase vs tamoxifen studies (Nabholtz
et al, 2000).
The median figure of d31402.6 for treating a relapse is higher
than previous UK estimates and this is largely due to the 30.3% of
community costs not collected earlier. Even though this data set is
the most up to date at the time of publication, these figures
represent the last 6 years, and are therefore still likely to
underestimate future costs. The full impact of herceptin, for
example, was not fully appreciated. Routine use of herceptin in the
metastatic setting within our institution was introduced in
November 2006, almost halfway through the evaluation period.
This meant that only 7 of the 16 HER2-overexpressing patients
received herceptin as part of their metastatic management. The
average cost of herceptin in treated patients was d15834.6.
According to the original published herceptin metastatic trial
data, these patients, on average, could have lived 5 months longer
(Vogel et al, 2002). In theory, therefore, if the remaining nine
patients had received herceptin and each lived 5 months longer,
this factor alone would have increased the total cost to over
d34200 per patient.
There is no doubt that newer biological agents, such as oral
tyrosine kinase inhibitors and antiangiogenesis drugs, will also
substantially add to the metastatic drug costs and as they will keep
relapsed patients alive for longer, this will also increase their non-
drug costs. The authors intend to repeat the same data-collection
exercise every 2 years using the same methodology to give an
ongoing estimate of the cost of a relapse, as these newer biological
agents evolve into clinical practice. In the mean time, these data by
including the community cost improve the accuracy of the cost-
effectiveness analysis of adjuvant breast cancer therapies.
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